Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134923 · ClinicalTrials.gov registry record
Imaging Biomarkers in Preclinical and Symptomatic AD
A clinical trial of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
- Recruiting
- Registry status
- 375
- Enrollment target
- 1
- Study location
NCT04134923: Recruiting study of Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.
NCT04134923 is a study of Alzheimer Disease that is actively recruiting participants, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 375 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04134923, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Tammie L. S. Benzinger, MD, PhD.
- RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).
Primary Outcome
the annual rate of CDR progression will accelerate due to the aging of the ACS cohort., and estimate that among \~375 ACS participants who either remain CDR 0 currently and will continue to be clinically assessed or will be the new future enrollees, a total of 45 individuals will progress to CDR\>0 by the end of next funding cycle.
Conditions Studied
Interventions
- DRUG [11C] Pittsburgh Compound-B (PIB)
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2029-10 |
What NCT04134923 shows while recruiting
NCT04134923 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [11C] Pittsburgh Compound-B (PIB) is the first listed.
NCT04134923 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04134923 about?
NCT04134923 is a clinical study titled "Imaging Biomarkers in Preclinical and Symptomatic AD". The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of a...
What is the current status of trial NCT04134923?
This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2021-06-08. Estimated completion is 2029-10.
What conditions does trial NCT04134923 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04134923?
The interventions under investigation include: [11C] Pittsburgh Compound-B (PIB) (DRUG).
Who is sponsoring clinical trial NCT04134923?
This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04134923 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04134923's enrollment target sits among peer trials
375 66th of 306 higher than 241 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
- NCT04571658 · 375 participants · NA
NEPTUNE Match Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI